Summit Research Development vs Interest Expense Analysis

SMMT Stock

USD 21.10 0.21 1.01%

Summit Therapeutics financial indicator trend analysis is much more than just breaking down Summit Therapeutics PLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Summit Therapeutics PLC is a good investment. Please check the relationship between Summit Therapeutics Research Development and its Interest Expense accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Research Development vs Interest Expense

Research Development vs Interest Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Summit Therapeutics PLC Research Development account and Interest Expense. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Summit Therapeutics' Research Development and Interest Expense is 0.45. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Summit Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Summit Therapeutics' Research Development and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Summit Therapeutics PLC are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Research Development i.e., Summit Therapeutics' Research Development and Interest Expense go up and down completely randomly.

Correlation Coefficient

0.45

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Research Development

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Most indicators from Summit Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Summit Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At this time, Summit Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 35.83 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (19.78) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	281K	4.4M	16.5M	17.3M
Depreciation And Amortization	2.5M	2.5M	2.1M	1.5M

Interest Expense Depreciation And Amortization

Summit Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Net Receivables	Short Term Investments
Total Assets		0.6	0.77	0.76	0.71	0.82	-0.48	-0.24	0.97	0.1	0.2	0.02	0.96	-0.31	0.39	0.97	-0.13	0.53	0.98	1.0	0.32	-0.19	0.97	0.25	0.1	0.21
Other Current Liab	0.6		0.81	0.64	0.38	0.27	-0.08	0.23	0.64	0.46	0.14	0.23	0.48	-0.21	-0.03	0.53	0.32	0.15	0.56	0.58	0.66	-0.22	0.52	-0.39	0.65	-0.2
Total Current Liabilities	0.77	0.81		0.77	0.59	0.35	-0.36	0.26	0.78	0.55	0.38	0.31	0.7	-0.48	0.21	0.67	0.23	0.41	0.71	0.74	0.76	-0.42	0.64	-0.05	0.62	0.03
Total Stockholder Equity	0.76	0.64	0.77		0.66	0.33	-0.44	-0.06	0.78	0.47	0.46	0.26	0.75	-0.44	0.33	0.61	0.09	0.51	0.64	0.74	0.5	-0.29	0.62	0.33	0.42	0.14
Property Plant And Equipment Net	0.71	0.38	0.59	0.66		0.53	-0.93	-0.18	0.57	0.22	0.3	0.13	0.87	-0.37	0.86	0.61	-0.21	0.96	0.63	0.7	0.37	-0.1	0.61	0.44	0.04	0.76
Net Debt	0.82	0.27	0.35	0.33	0.53		-0.4	-0.47	0.74	-0.36	-0.15	-0.24	0.79	0.02	0.38	0.9	-0.39	0.41	0.88	0.84	-0.06	0.12	0.91	0.22	-0.37	0.3
Retained Earnings	-0.48	-0.08	-0.36	-0.44	-0.93	-0.4		0.15	-0.29	-0.19	-0.34	-0.09	-0.7	0.28	-0.96	-0.38	0.28	-0.99	-0.4	-0.47	-0.27	-0.02	-0.38	-0.53	0.14	-0.92
Accounts Payable	-0.24	0.23	0.26	-0.06	-0.18	-0.47	0.15		-0.25	0.63	0.32	0.06	-0.28	-0.25	-0.16	-0.32	0.78	-0.13	-0.28	-0.28	0.73	-0.33	-0.35	-0.44	0.67	-0.18
Cash	0.97	0.64	0.78	0.78	0.57	0.74	-0.29	-0.25		0.1	0.19	0.06	0.88	-0.3	0.19	0.95	-0.1	0.35	0.96	0.97	0.29	-0.23	0.95	0.19	0.17	0.0
Non Current Assets Total	0.1	0.46	0.55	0.47	0.22	-0.36	-0.19	0.63	0.1		0.68	0.46	0.12	-0.4	0.09	-0.07	0.47	0.24	-0.02	0.04	0.8	-0.37	-0.09	-0.15	0.66	0.02
Non Currrent Assets Other	0.2	0.14	0.38	0.46	0.3	-0.15	-0.34	0.32	0.19	0.68		0.35	0.27	-0.04	0.26	0.07	0.1	0.36	0.1	0.16	0.45	0.05	0.06	0.32	0.25	0.11
Other Assets	0.02	0.23	0.31	0.26	0.13	-0.24	-0.09	0.06	0.06	0.46	0.35		0.02	-0.12	-0.11	-0.08	-0.33	0.12	-0.05	-0.01	0.16	-0.24	-0.07	0.2	0.45	-0.08
Cash And Short Term Investments	0.96	0.48	0.7	0.75	0.87	0.79	-0.7	-0.28	0.88	0.12	0.27	0.02		-0.36	0.62	0.91	-0.21	0.74	0.92	0.95	0.3	-0.16	0.91	0.4	0.0	0.47
Common Stock Total Equity	-0.31	-0.21	-0.48	-0.44	-0.37	0.02	0.28	-0.25	-0.3	-0.4	-0.04	-0.12	-0.36		-0.25	-0.21	-0.25	-0.33	-0.24	-0.29	-0.42	0.93	-0.18	-0.08	-0.34	-0.22
Common Stock Shares Outstanding	0.39	-0.03	0.21	0.33	0.86	0.38	-0.96	-0.16	0.19	0.09	0.26	-0.11	0.62	-0.25		0.31	-0.21	0.94	0.33	0.39	0.18	0.06	0.31	0.47	-0.26	0.94
Non Current Liabilities Total	0.97	0.53	0.67	0.61	0.61	0.9	-0.38	-0.32	0.95	-0.07	0.07	-0.08	0.91	-0.21	0.31		-0.2	0.42	1.0	0.98	0.2	-0.12	1.0	0.19	-0.04	0.15
Other Current Assets	-0.13	0.32	0.23	0.09	-0.21	-0.39	0.28	0.78	-0.1	0.47	0.1	-0.33	-0.21	-0.25	-0.21	-0.2		-0.25	-0.17	-0.16	0.64	-0.28	-0.23	-0.56	0.62	-0.3
Other Stockholder Equity	0.53	0.15	0.41	0.51	0.96	0.41	-0.99	-0.13	0.35	0.24	0.36	0.12	0.74	-0.33	0.94	0.42	-0.25		0.45	0.52	0.31	-0.04	0.42	0.52	-0.08	0.9
Total Liab	0.98	0.56	0.71	0.64	0.63	0.88	-0.4	-0.28	0.96	-0.02	0.1	-0.05	0.92	-0.24	0.33	1.0	-0.17	0.45		0.99	0.25	-0.15	0.99	0.18	0.01	0.16
Total Current Assets	1.0	0.58	0.74	0.74	0.7	0.84	-0.47	-0.28	0.97	0.04	0.16	-0.01	0.95	-0.29	0.39	0.98	-0.16	0.52	0.99		0.27	-0.17	0.98	0.26	0.06	0.21
Intangible Assets	0.32	0.66	0.76	0.5	0.37	-0.06	-0.27	0.73	0.29	0.8	0.45	0.16	0.3	-0.42	0.18	0.2	0.64	0.31	0.25	0.27		-0.35	0.17	-0.3	0.71	0.07
Common Stock	-0.19	-0.22	-0.42	-0.29	-0.1	0.12	-0.02	-0.33	-0.23	-0.37	0.05	-0.24	-0.16	0.93	0.06	-0.12	-0.28	-0.04	-0.15	-0.17	-0.35		-0.09	0.07	-0.45	0.07
Short Long Term Debt Total	0.97	0.52	0.64	0.62	0.61	0.91	-0.38	-0.35	0.95	-0.09	0.06	-0.07	0.91	-0.18	0.31	1.0	-0.23	0.42	0.99	0.98	0.17	-0.09		0.21	-0.06	0.16
Current Deferred Revenue	0.25	-0.39	-0.05	0.33	0.44	0.22	-0.53	-0.44	0.19	-0.15	0.32	0.2	0.4	-0.08	0.47	0.19	-0.56	0.52	0.18	0.26	-0.3	0.07	0.21		-0.31	0.46
Net Receivables	0.1	0.65	0.62	0.42	0.04	-0.37	0.14	0.67	0.17	0.66	0.25	0.45	0.0	-0.34	-0.26	-0.04	0.62	-0.08	0.01	0.06	0.71	-0.45	-0.06	-0.31		-0.35
Short Term Investments	0.21	-0.2	0.03	0.14	0.76	0.3	-0.92	-0.18	0.0	0.02	0.11	-0.08	0.47	-0.22	0.94	0.15	-0.3	0.9	0.16	0.21	0.07	0.07	0.16	0.46	-0.35

Click cells to compare fundamentals

Summit Therapeutics Account Relationship Matchups

Summit Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	96.9M	102.5M	113.4M	664.2M	202.9M	213.1M
Other Current Liab	6.2M	5.0M	12.2M	17.0M	717K	681.2K
Total Current Liabilities	12.7M	19.9M	25.6M	38.8M	20.4M	11.0M
Total Stockholder Equity	78.5M	79.5M	83.3M	126.7M	77.7M	39.6M
Property Plant And Equipment Net	1.5M	1.3M	3.5M	5.1M	6.1M	6.4M
Net Debt	(63.2M)	(66.0M)	(69.0M)	170.2M	34.7M	36.4M
Retained Earnings	(125.3M)	(214.7M)	(299.5M)	(378.3M)	(993.3M)	(943.6M)
Accounts Payable	4.5M	6.1M	4.4M	355K	2.7M	4.2M
Cash	64.1M	66.4M	71.8M	348.6M	71.4M	47.0M
Non Current Assets Total	17.1M	36.1M	16.1M	7.5M	13.2M	12.3M
Non Currrent Assets Other	4.2M	21.3M	170K	577K	5.3M	5.5M
Other Assets	1.0	(16.4M)	25.5M	577K	663.6K	710.0K
Cash And Short Term Investments	64.1M	66.4M	71.8M	348.6M	186.2M	195.6M
Common Stock Shares Outstanding	164.1M	69.5M	92.2M	193.3M	619.6M	650.6M
Liabilities And Stockholders Equity	96.9M	102.5M	113.4M	664.2M	202.9M	213.1M
Non Current Liabilities Total	5.7M	3.2M	4.5M	498.7M	104.9M	110.1M
Other Current Assets	8.8M	1.5M	1.2M	486K	181K	172.0K
Other Stockholder Equity	171.0M	293.4M	384.0M	504.8M	1.1B	1.1B
Total Liab	18.4M	23.0M	30.1M	537.5M	125.3M	131.5M
Total Current Assets	79.7M	66.4M	97.3M	656.7M	189.7M	199.2M
Accumulated Other Comprehensive Income	28.3M	(3.8M)	(2.2M)	(1.9M)	(2.4M)	(2.3M)
Intangible Assets	13.9M	9.9M	11.5M	10.4M	12.0M	7.4M
Common Stock	4.4M	826K	980K	2.1M	7.0M	4.7M
Short Long Term Debt Total	898.2K	465K	2.8M	518.8M	106.1M	111.4M
Current Deferred Revenue	4.4M	1.5M	8.4M	7.9M	14.2M	14.9M
Net Receivables	6.8M	10.2M	17.2M	6.1M	848K	805.6K
Inventory	2.0	(11.7M)	7.2M	301.5M	2.4M	2.3M
Property Plant And Equipment Gross	1.2M	1.3M	6.9M	6.4M	7.1M	7.5M
Short Term Debt	474.3K	390K	1.1M	21.5M	2.8M	4.0M
Good Will	2.4M	2.0M	2.0M	1.8M	1.9M	3.6M
Property Plant Equipment	1.2M	1.3M	3.5M	5.1M	5.8M	6.1M
Other Liab	4.0M	3.1M	2.8M	1.4M	1.3M	1.2M
Net Tangible Assets	47.5M	23.4M	70.9M	124.9M	143.6M	150.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC